4//SEC Filing
PURA VIDA INVESTMENTS, LLC 4
Accession 0001209191-22-039692
CIK 0001642380other
Filed
Jun 27, 8:00 PM ET
Accepted
Jun 28, 7:48 PM ET
Size
14.3 KB
Accession
0001209191-22-039692
Insider Transaction Report
Form 4
PURA VIDA INVESTMENTS, LLC
10% Owner
Transactions
- Sale
Common Stock
2022-06-24$1.03/sh−40,464$41,552→ 8,479,682 total(indirect: By the Managed Accounts.) - Sale
Common Stock
2022-06-24$1.05/sh−12,517$13,160→ 8,520,146 total(indirect: By the Managed Accounts.) - Sale
Common Stock
2022-06-24$1.03/sh−35,441$36,394→ 7,427,202 total(indirect: By Pura Vida Master Fund, Ltd.) - Sale
Common Stock
2022-06-24$1.05/sh−10,964$11,528→ 7,462,643 total(indirect: By Pura Vida Master Fund, Ltd.)
Kamen Efrem
10% Owner
Transactions
- Sale
Common Stock
2022-06-24$1.05/sh−10,964$11,528→ 7,462,643 total(indirect: By Pura Vida Master Fund, Ltd.) - Sale
Common Stock
2022-06-24$1.03/sh−35,441$36,394→ 7,427,202 total(indirect: By Pura Vida Master Fund, Ltd.) - Sale
Common Stock
2022-06-24$1.05/sh−12,517$13,160→ 8,520,146 total(indirect: By the Managed Accounts.) - Sale
Common Stock
2022-06-24$1.03/sh−40,464$41,552→ 8,479,682 total(indirect: By the Managed Accounts.)
Footnotes (5)
- [F1]Aggregate number of shares sold on the same date at difference prices.
- [F2]Represents the weighted-average sales price. The shares were sold in multiple transactions at prices ranging from $1.04 to $1.09, inclusive, per share. Full information regarding the number of shares sold at each price shall be provided to the Securities and Exchange Commission staff (the "Staff), Issuer or any security holder, upon request.
- [F3]Shares reported herein are owned by Pura Vida Master Fund, Ltd. (the "Pura Vida Master Fund") and certain separately managed accounts (the "Managed Accounts," and together with the Pura Vida Master Fund, collectively the "Client Accounts"). Pura Vida Investments, LLC ("PVI") serves as the investment manager or sub-adviser to the Client Accounts. Efrem Kamen serves as the Managing Member of PVI.
- [F4]By virtue of these relationships, the Reporting Persons may be deemed to have shared voting and dispositive power with respect to the securities owned directly by the Client Accounts. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of the Reporting Person's pecuniary interest therein, if any.
- [F5]Represents the weighted-average sales price. The shares were sold in multiple transactions at prices ranging from $1.02 to $1.0475, inclusive, per share. Full information regarding the number of shares sold at each price shall be provided to the Staff, Issuer or any security holder, upon request.
Documents
Issuer
Oncocyte Corp
CIK 0001642380
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001590144
Filing Metadata
- Form type
- 4
- Filed
- Jun 27, 8:00 PM ET
- Accepted
- Jun 28, 7:48 PM ET
- Size
- 14.3 KB